NCT03684785: Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT03684785
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had disease progression during therapy with an anti-PD-(L)1 antibody to be eligible for the expansion phase
Exclusions: Patients with known active unstable CNS metastases and/or carcinomatous meningitis that require treatment – see trial for details; Patients who had had more than 3 prior lines of systemic treatment for metastatic disease are not eligible for the expansion phase
https://ClinicalTrials.gov/show/NCT03684785

Comments are closed.

Up ↑